Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma

Gelu-Siméon, Moana; Samuel, Didier

doi:10.1007/s12072-013-9441-4

Hepatol Int

2013

DOI: 10.1007/s12072-013-9441-4

|View full text |Cite

Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma

Moana Gelu-Siméon

Didier Samuel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCC impacts approximately 1 000 000 people every year worldwide [4]. The most noteworthy HCC predominance worldwide has been reported in Egypt [5,6]. Sorafenib, a multityrosine kinase inhibitor, is considered to be the only systemic treatment for patients who are not candidates for a locoregional cure [5,7].…”

mentioning

confidence: 99%

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

Shamaa

2021

FEBS Open Bio

View full text Add to dashboard Cite

The author investigated the potential anticarcinogenic effects of imatinib and sulfasalazine alone or in combination on HEPG2 and Huh‐7 cell lines. Combined use of both drugs inhibited cell growth and promoted apoptosis via the phosphoinositide 3‐kinase/protein kinase B, phosphorylated signal transducer and activator of translation 3 (p‐STAT‐3), breakpoint cluster region/Abelson proto‐oncogene and nuclear factor κB pathways. These results suggest that sulfasalazine synergistically potentiates the antitumor effect of imatinib.

show abstract

mentioning

confidence: 99%

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

Shamaa

2021

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Liver cancer is the sixth most common cancer worldwide and 3rd most common cause of cancer-related death. Hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancer and is a major public health problem. Due to the advanced stages of HCC at the time of diagnosis, utilizing the conventional treatment for solid tumors frequently ends with treatment failure, recurrence, or poor survival. HCC is highly refractory to chemotherapy and other systemic treatments, and locoregional therapies or selective internal radiation therapies are largely palliative. Considering how the pathogenesis of HCC often induces an immunosuppressed state which is further amplified by post-treatment recurrence and reactivation, immunostimulation provides a potential novel approach for the treatment of HCC. Immune response(s) of the body may be potentiated by immunomodulation of various effector cells such as B-cells, T-cells, Treg cells, natural killer cells, dendritic cells, cytotoxic T-lymphocytes, and other antigen-presenting cells; cellular components such as genes and microRNA; and molecules such as proteins, proteoglycans, surface receptors, chemokines, and cytokines. Targeting these effectors individually has helped in the development of newer therapeutic approaches; however, combinational therapies targeting multi-faceted biomarkers have yielded better results. Still, there is a need for further research to develop novel therapeutic strategies which may act as either complementary or an alternative treatment to the standard therapy protocols of HCC. This review focuses on potential cellular and molecular targets, as well as the role of virotherapy and combinational therapy in the treatment of HCC.

show abstract

Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges

Wang

2019

Hepatol Int

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma

Cited by 3 publications

References 23 publications

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins

Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma

Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges

Contact Info

Product

Resources

About